Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rakhi Salve"'
Autor:
Manju Sengar, Rakhi Salve, Chinmayee Kakirde, Prasanna Bhanshe, Papagudi Ganesan Subramanian, Anam Fatima Shaikh, Shruti Chaudhary, Bhausaheb Bagal, Rohan Kodgule, Hasmukh Jain, Sitaram Ghoghale, Nikhil Patkar, Syed Hasan Khizer, Sumeet Gujral, Prashant Tembhare, Nilesh Deshpande, Sweta Rajpal, Swapnali Joshi, Gaurav Chatterjee, Hari Menon, Navin Khattry, Dhanalaxmi Shetty
Publikováno v:
Leukemia
We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission, and evaluated MRD using sensitive error-corrected next generation sequencing (NGS-MRD) and multiparameter flow cytometry (FCM-MRD) at the end of induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75a21e7afb557198f1d9d0c12dc650d
https://doi.org/10.1038/s41375-021-01131-6
https://doi.org/10.1038/s41375-021-01131-6
Autor:
Dhanalaxmi Shetty, Nikhil Patkar, Prashant Tembhare, Sumeet Gujral, Rohan Kodgule, Manju Sengar, Papagudi Ganesan Subramanian, Rakhi Salve, Nilesh Deshpande, Sitaram Ghoghale, Navin Khattry, Shruti Chaudhary, Sweta Rajpal, Hasmukh Jain, Anam Fatima Shaikh, Chinmayee Kakirde, Hari Menon, Bhausaheb Bagal, Syed Hasan Khizer, Prasanna Bhanshe, Gaurav Chatterjee, Swapnali Joshi
We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission and evaluated MRD using sensitive error corrected next generation sequencing (NGS-MRD) and multiparameter flow cytometry (FCM-MRD) at the end of induct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098af08cdead7bc860d17a866fec672a
Autor:
Manju Sengar, Prasanna Bhanshe, Sweta Rajpal, Dhanlaxmi Shetty, Rakhi Salve, Anam Fatima Shaikh, Bhausaheb Bagal, Sumeet Gujral, Chinmayee Kakirde, Rohan Kodgule, Prashant Tembhare, Shruti Chaudhary, Hasmukh Jain, Papagudi Ganesan Subramanian, Nikhil Patkar, Hari Menon, Swapnali Joshi, Navin Khattry, Gaurav Chatterjee
Publikováno v:
Blood. 136:5-6
Introduction The monitoring of a patient's response to chemotherapy, called, measurable residual disease (MRD) is one of the most important predictors of outcome in Acute Myeloid Leukemia (AML). Although universally applicable, FCM-MRD for AML suffer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0abdc72377f372708e5dacd81ae917b1
https://doi.org/10.1182/blood-2020-143457
https://doi.org/10.1182/blood-2020-143457